Related content

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens

By                    

Oncology Letters, Vol. 2, Iss. 2, 2011-01 ,pp. : 241-245

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer

By Kusaba Hitoshi   Esaki Taito   Kishimoto Junji   Uchino Keita   Arita Shuji   Kumagai Hozumi   Mitsugi Kenji   Akashi Koichi   Baba Eishi  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 29-34

Springer Publishing Company

Access to resources Recommend Favorite

Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer

By Choi In   Lee Keun-Wook   Kim Ki   Kim Yu   Kim Jee   Lee Jong  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 992-997

Humana Press, Inc

Access to resources Recommend Favorite

Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study

By Seto Takashi   Takezako Yoriko   Nakamura Hiroko   Takeda Kayo   Inoue Fumiko   Semba Hiroshi   Eguchi Kenji  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 378-382

Springer Publishing Company

Access to resources Recommend Favorite

Second-line chemotherapy for advanced gastric cancer in Korea

By Baek Sun   Kim Si-Young   Jeong Jae-heon   Cho Kyung   Yoon Hwi-Joong  

Gastric Cancer, Vol. 15, Iss. 4, 2012-10 ,pp. : 345-354

Springer Publishing Company

Access to resources Recommend Favorite